AJR 2005; 184:S138-S145
© American Roentgen Ray Society
Issues, Controversies, and Clinical Utility of Combined PET/CT Imaging: What Is the Interpreting Physician Facing?
Todd M. Blodgett1,
Bethany Casagranda1,
David W. Townsend1 and
Carolyn C. Meltzer1,2
1 Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop
St., Pittsburgh, PA 15213.
2 Departments of Psychiatry and Neurology, University of Pittsburgh Medical
Center, Pittsburgh, PA 15213.
Received November 1, 2004;
accepted after revision November 19, 2004.
Address correspondence to T. M. Blodgett. Todd Blodgett is a consultant and
speaker for PETNET Solutions.
CONTINUING MEDICAL EDUCATION
This article is available for 1 hour of Category 1 CME credit. It is free
to ARRS members, and may be purchased by non-members for $10.00. Detailed
information including objectives, disclosure information, and how to obtain
CME credit can be found at
www.arrs.org
by selecting the AJR Technology Forum link.
This article is also available on the AJR website at
www.ajronline.org.
Abstract
OBJECTIVE. This article identifies the most commonly encountered
issues of combined PET/CT and shows the wide variability in perceived possible
solutions to these issues. This article will serve as a catalyst to stimulate
discussion between experts in both radiology and nuclear medicine.
CONCLUSION. Combining a PET tomography and CT scanner into a single
unit amounts to advantages that are not merely additive, but synergistic. Even
PET/CT skeptics will embrace the technology after becoming acquainted with the
possibilities and will accept the reality that there is no return to PET
only.
Introduction
Combined PET/CT scanners became commercially available in the United
States in the spring of 2001. Within 3 years, over 450 PET/CT scanners will
have been sold worldwide, with the majority being in the United States. PET/CT
scanner sales currently account for over 80% of the PET scanner market.
Although all of the potential benefits of a combined PET/CT scanner are not
immediately obvious, the rapid proliferation of scanners suggests realized
benefits and also provides testimony to its rapid acceptance as the new
standard in oncologic imaging. Clearly, combining a PET tomography and CT
scanner into a single unit amounts to advantages that are not merely additive,
but synergistic. Even PET/CT skeptics will embrace the technology after
becoming acquainted with the possibilities and accept the reality that there
is no return to PET only.
As with most new imaging techniques, there are both software and hardware
hurdles that continue to be examined; however, there has been a steady
evolution in the design and implementation of the technique, with 16-MDCT (and
greater) scanners and high-resolution PET scanners being incorporated into
current commercial PET/CT devices. Referring clinicians have been eager to use
PET/CT to evaluate their patients, not only because it promises superior
diagnostic capabilities, but also because PET/CT offers imaging consolidation,
faster scan times, and added advantages for radiation therapy planning that
PET and CT separately simply do not offer. However, the variability in PET/CT
protocols (particularly how the CT portion of the examination is performed),
ways in which the scans are interpreted and by whom, and variability in
reporting methods have led to many questions by referring clinicians, such as
"I thought I had ordered a PET/CT, why do I need to order another CT
scan?" "Why do I get two separate reports by two different
interpreting physicians?" "What do you mean the CT is not a
diagnostic CT?"
Nuclear medicine physicians and radiologists also are understandably
excited about a new fusion imaging technique that has shown great promise in
oncologic imaging, although their excitement is somewhat tempered by the
complexities of successfully introducing this new technique into clinical
practice, including where the scanner will reside (in radiology or nuclear
medicine), and several difficult operational, educational, personnel,
protocol, and legal issues. As a consequence, interpreting physicians
ultimately have many questions, such as "where do I get the needed
cross-training to read PET/CT?" "What amount of training is
necessary?" "Does the CT portion of a PET/CT need to be
interpreted?" "Are dual readouts between nuclear medicine
physicians and radiologists necessary?" "Should I do CT with or
without contrast?"
It is clear that the fusion of CT with PET represents not only a simple
combination of anatomy (CT) with function (PET), but also a complex symbolic
and real-life fusion of radiology with nuclear medicine, with the scanner
serving as the catalyst for the inevitable union. Nuclear medicine has
struggled for many years to establish PET in the mainstream of imaging, and
through the many supporting studies over the past 20 years, PET has become the
backbone of nuclear medicine, historically established in nuclear medicine
departments; now, however, PET/CT threatens this stability.
With the increasing installation of PET/CT scanners in radiology
departments, many radiologists are relying on consultation with their nuclear
medicine colleagues and, at some institutions, there are joint readouts
between nuclear medicine physicians and radiologists. Some will undoubtedly
argue over whether PET/CT belongs in radiology or nuclear medicine but,
certainly, the ultimate success of the technique will depend on the
cooperation and collaboration of both disciplines.
18F-Flurodeoxyglucose (18F-FDG) is no more a simple
contrast agent than a CT scan is a simple localization device that can
serendipitously function as a method of performing attenuation correction.
The goal of this introductory article is to identify the most commonly
encountered issues of combined PET/CT and show the wide variability in
perceived possible solutions to the many issues surrounding PET/CT. This
discussion will serve as a catalyst to stimulate discussion between experts in
both radiology and nuclear medicine.
Reasoning for This Supplement
At the ARRS annual meeting in May 2004, several PET, CT, and "dually
trained" physicians were invited to participate in an interactive
session titled "PET/CT Unplugged." The purpose of this session was
to identify and discuss as many of the complex operational, training, legal,
and interpretation issues as possible in an inclusive bipartisan expert panel
setting. The objective was to emerge with a consensus statement, with four
specific goals in mind:
- Identify pertinent training, hardware, legal, and operational issues unique
to PET/CT.
- Stimulate discussion between nuclear medicine and radiology in a
collaborative effort proactively to identify possible ways to improve patient
care and preserve mutual involvement.
- Summarize consensus recommendations to serve as a reference and as a means
of reducing the wide variability in theoretic solutions.
- Serve as a catalyst to stimulate further discussion.
There is little or no debate that the best outcome for patient care is a
true collaborative effort by both nuclear medicine and radiology. To assess
the variability in perceived possible solutions to the many issues addressed
at the ARRS meeting, a survey was constructed by participants of the PET/CT
consensus panel. Standardized surveys were distributed to radiologists,
nuclear medicine physicians, and dually trained physicians with experience in
PET/CT interpretation at several academic institutions, community imaging
centers, and outpatient PET centers to gather information on the current
opinions and range of possible solutions to the many complex issues
surrounding PET/CT. Although these data previously were unpublished, the range
of responses to some of the most commonly asked questions will be included in
this first article to show the need for ongoing discussion and cooperative
consensus recommendations.
Training
PET/CT requires expertise in both cross-sectional CT, and a thorough
understanding of PET. Currently, there are a limited number of dually trained
physicians, i.e, those who have completed a radiology residency and nuclear
medicine residency and/or PET fellowship. As the technique continues to
proliferate, there will be an increased need and demand for dually trained
interpreting physicians.
The first section of the multiinstitutional survey focused on training
issues. Because there is a lack of programs designed to offer comprehensive
training to either radiologists or nuclear medicine physicians seeking to
acquire skills in PET/CT, the first set of questions addressed respondents'
perceptions of reasonable training requirements and what would be reasonable
training curricula for future trainees. The "reasonable PET training
requirements" (days of training and supervised scan interpretations) for
radiologists ranged from 3 days to a full year of PET fellowship and 25-500
supervised scans. The "reasonable cross-sectional CT training
requirements" for nuclear medicine physicians ranged from 3 months to a
4-year radiology residency. Answers were biased based on the background
training of the physicians. To complicate matters, there are no current
training guidelines, recommendations, or certification programs for either
nuclear medicine physicians or radiologists for PET/CT. Although there are
several 1-day to 2-week PET and PET/CT courses for radiologists to improve
their PET skills, there are few yearlong PET and PET/CT fellowships and, only
more recently, are there courses aimed at teaching nuclear medicine physicians
pertinent cross-sectional CT anatomy. These programs, however, have no
established curricula or certification requirements. Clearly, training
recommendations from experts in both fields with overview and support by
professional societies are warranted. Although nothing has been published,
training recommendations currently are under consideration by a joint
committee including the Society of Nuclear Medicine and the American College
of Radiology.
CT Issues
There is wide variability in the quality of CT scanners installed within
PET/CT units today and there are many different CT protocols in use. One
important and complex decision that must be made is whether IV contrast will
be used, which requires appropriate medical coverage for possible untoward
contrast reactions. There also still is debate as to whether IV and/or oral
contrast add complementary or additional information to a PET/CT scan. There
are also questions concerning the use of CT-based attenuation correction when
the CT scan is acquired with contrast because using IV contrast can negatively
affect the calculation of the CT-based attenuation correction. The concern is
the potential of CT contrast to generate artifacts on the PET scan. Most
radiologists agree that when there is a questionable abnormality detected on
the PET portion of the examination, having well-opacified vessels and bowel
improves their confidence level and specificity in differentiating benign from
malignant FDG uptake regardless of the amount of FDG uptake.
Among the survey respondents, 55% felt that all CT scans performed as part
of a PET/CT should be with oral and IV contrast. As might be expected,
radiologists recommended the use of contrast more often than nuclear medicine
physicians did, although there were several nuclear medicine physicians who
recommended routine use of contrast. Eighty percent of dually trained
physicians polled recommended routine use of oral and IV contrast, which
suggests that when nuclear medicine physicians have additional training in
radiology, they generally prefer contrast. Compared with nuclear medicine
physicians in the community setting, those at academic institutions also
suggested the routine use of oral and IV contrast. However, many of the
community-based nuclear medicine physicians commented that the main reason
they did not perform contrast-enhanced studies was a lack of medical
coverage.
Among the interpreting physicians at academic institutions who thought the
scans should be done with contrast, 58% also thought that additional CT
protocol considerations, such as timing/rate of the contrast bolus and
additional hepatic artery phase or delayed CT scans for certain tumors would
likely add additional information that could prove helpful in making a
diagnosis by PET/CT.
For unenhanced CT scans, there are generally two methods currently in use:
full dose (140 mA) and low dose (as low as 40 mA). Some centers are using
low-dose CT, occasionally referred to as "nondiagnostic CT," for
attenuation correction and localization purposes, and are including a
disclosure that the scan is not being performed for diagnostic purposes.
However, there are several legal and logistical concerns with this technique;
these are described in more detail in other articles within this supplement
series. As with many of the training issues, it is clear that there is wide
variability in the perceived right way or best way to do the CT portion of a
PET/CT examination.
Legal
The "PET/CT Unplugged" participants had two main legal
concerns, which were included in the multiinstitutional survey: Does the CT
portion of a PET/CT have to be interpreted, and can an interpreting physician
who misses a finding on a CT portion of a PET/CT be held liable if a strongly
worded disclaimer is used in the report stating that the CT portion of the
examination is only being used for attenuation correction and localization
purposes? There were sharply differing opinions on these issues when asked
without discussion (on the survey), with many physicians unsure of the correct
answer. However, many survey respondents were justifiably concerned about the
possible legal ramifications of performing nondiagnostic CT scans, whether low
dose or not, with the obvious risk of overlooking diagnostic information,
simply because the CT portion of an otherwise negative PET/CT was never
examined.
Additional legal concerns involved the opinions regarding the Stark Law,
which is legislation that forbids entrepreneurial ownership of CT scanners by
making it unlawful to bill for such examinations. However, nuclear medicine
devices in general, and PET in particular, do not fall under the Stark Law,
making it possible for a physician or group of physicians to own a PET or
PET/CT scanner, provided the CT portion of the examination is not billed.
There are several potential ethical concerns given the current way the law is
written, and quality assurance issues. Certainly, the potential for
self-referral is present in the case of an oncologist or group of oncologists
who have a financial interest in the success of a PET or PET/CT center. There
also is a potential conflict of interest for a group of interpreting and
referring clinicians to have ownership interests. Clearly, discussion of these
legal issues is imperative to protect patients and physicians alike.
Interpretation and Reporting
Images from a PET/CT scan generally can be interpreted using one of three
methods, although there are several iterations of these three methods: (1) A
single dually-trained physician with adequate radiology and PET experience can
interpret the entire examination, (2) a radiologist and nuclear medicine
physician can hold a joint readout session, or (3) the study may be split with
the CT portion of the examination interpreted by a radiologist and the PET
images interpreted by a nuclear medicine physician, hopefully with
corroboration. Eighty-four percent of survey respondents thought that a single
dually trained physician interpretation is the optimal method, while just 16%
felt that joint readouts would be optimal, occasionally commenting that dual
readouts provide "another set of eyes." Although no one suggested
that interpretation by a singly trained physician or splitting of the
examinations with hopeful corroboration were the most ideal scenarios, this
currently is used at many academic and community centers. Whether due to
physical separation of nuclear medicine and radiology departments or due to
other logistical restraints, such as large patient volume or inadequate
staffing issues, these suboptimal methods currently are being used.
There are also several different reporting options. These will depend
largely on how the study is performed (particularly how the CT is performed
and whether it will be charged), by whom the study will be interpreted, and by
the development of dual ICD/CPT codes, which may narrow the possible methods
for reporting. Seventy-four percent of survey respondents thought that a
single report was the most useful, both for optimizing patient care and for
the benefit of referring clinicians. However, many interpreting physicians
fear that reimbursement may be negatively affected by dual CPT or billing
codes by disallowing the ability to bill for both PET and CT. There are many
potential problems with a dual interpretation/reporting method, the most
extreme being the presence of discordant CT and PET reports in situations
where the findings have not been corroborated by both the nuclear medicine
physician and radiologist. Until dual codes are implemented, it is likely that
insurance companies also will dictate to a degree the reporting methods used,
with most currently requiring separate reports for CT and PET when both are
charged to third party payers.
Clinical Utility of PET/CT Imaging
PET/CT has become the standard for oncologic imaging. Although PET and CT
done separately will continue to exist, particularly in the European and other
foreign markets that have stronger utilization restrictions, the trend is
certainly moving toward hardware fusion imaging (PET/CT) for the evaluation of
most malignancies. As of October 2004, there were approximately 150 papers in
the literature discussing some aspect of combined PET/CT, most highlighting
some advantage of PET/CT over PET, CT, or PET and CT done separately.
There are alternatives to hardware fusion imaging, such as the
software-based approaches that have been developed over the past 15 years or
more
[1-7].
Retrospective image registration by software is useful for certain
applications, particularly when examining rigid structures, such as the brain,
where it is relatively easy to attain accurate coregistration of images
because the brain is a fixed structure within the cranial vault. These
retrospective registration programs tend to be less useful for nonrigid
applications, particularly in the neck and abdominopelvic regions where there
is much greater potential for differences in patient positioning and organ
movement. Reliance on accurate coregistration is nowhere more apparent than
with lesions that are not visible on CT. This is precisely when reliance on
accurate image coregistration is so important, and in these instances, it is
impossible to be completely confident in localized software
coregistration.
Other obvious benefits of performing combined PET/CT over PET and CT done
separately include consolidation of the patient's imaging procedures, faster
scan times and increased patient throughput (by not having to do a separate
PET transmission scan), and the ability to use the technique for radiation
therapy planning.
The most noticeable clinical benefit of combined PET/CT is improved lesion
localization, with several authors reporting significant changes and
improvement in lesion localization when comparing the PET portion of a PET/CT
with full access to the fused PET/CT images
[8-12].
One of the most frustrating aspects of FDG PET alone is the lack of anatomic
detail and the uncertainty in localizing many areas of FDG accumulation. It is
often difficult or impossible to differentiate specific areas of FDG uptake as
physiologic or pathologic. By providing the ability to fuse accurately
coregistered PET and CT data sets, PET/CT significantly reduces the magnitude
of mislocalization of FDG uptake and improves the confidence level of the
interpreting physicians in precisely localizing potential lesions. Many
authors have also published case reports and case series describing how
visualizing the fused images helped resolve potential misinterpretation of
benign processes as malignant
[13-22].
In addition, PET/CT has been reported to affect patient management,
particularly in radiation therapy evaluation and planning
[8,
23-28].
Patients undergoing radiation therapy planning have traditionally had their
planning based solely on anatomic information from a CT scan performed with an
approved radiation therapy immobilization pallet. With PET/CT, which can
accommodate such radiation therapy pallets, both the CT and PET (fused) data
sets can be exported from the acquisition workstation and imported into most
planning software systems. The majority of these software packages have
available up-grades with the ability to do fusion of one or more DICOM data
sets. Contouring then can be performed, taking into consideration not only the
anatomic information but also the metabolic data. This is particularly
important when there are lesions that do not show any definite anatomic
abnormality. When the lesion cannot be identified on the CT portion of the
examination, radiation oncologists must rely on the metabolic or PET data for
their contouring.
In the last 3 years, several reports have also emerged demonstrating the
improved performance and incremental value of PET/CT over PET, CT, or PET and
CT performed separately for staging patients with both Hodgkin's and
non-Hodgkin's lymphoma, and lung and colorectal cancer
[28-34].
One of the most beneficial applications of combined PET/CT is in restaging
patients who have undergone extensive surgery or who have had significant
levels of radiation, both of which tend to distort normal anatomy and cause
inflammatory changes. The importance and utility of PET/CT in the restaging of
several malignancies, including head and neck, colorectal, thyroid, ovarian
cancer, and lymphoma also have been reported
[29,
32,
35-42].
Additional Benefits of PET/CT In Terms of Lesion Localization
PET Lesions Not Seen on CT
The lesions for which the added benefits of combined PET/CT are the most
apparent are lesions that are not visible on the CT portion of the
examination. Radiologists depend on a number of criteria for determining
whether a lesion is benign or malignant, including size, enhancement, mass
effect, and the presence or absence of necrosis. However, many lesions,
depending on their location and stage, do not show any anatomic abnormalities
on CT (Fig. 1). Occasionally,
even contrast enhancement will not make the lesions more visible. Often PET
alone will detect the presence of disease by demonstrating an area of
increased metabolism, but without an abnormality on the correlative anatomic
imaging study, it becomes very difficult to localize accurately these lesions.
With PET/CT, as long as the coregistration is accurate (i.e., minimal patient
movement between CT and PET portions of the examination), it is possible not
only to detect the presence of disease, but also to more accurately convey the
location to referring clinicians.

View larger version (96K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1. Lesions not seen on CT: PET/CT performed 4 months after
resection in patient who did not undergo initial staging with PET or PET/CT.
Although CT scan is essentially normal even with good contrast enhancement,
patient had three small lesions (arrows) compatible with widespread
metastatic disease. If lesions were present and identified using PET/CT, an
unnecessary thoracotomy would have been avoided.
|
|
PET Lesions Obscured by CT Artifacts
It has become essential for interpreting PET physicians to have some type
of correlative anatomic imaging to corroborate identified abnormalities.
Occasionally, the lesion may not be seen due to overlying or obscuring
artifacts. Artifacts such as streak or beam hardening can make it difficult or
impossible to see a small lymph node or an area of soft-tissue abnormality.
Before PET/CT, an interpreting PET physician would describe the general
location of the abnormality and usually convey that further precision was not
possible due to an overlying artifact. Although detecting the presence of and
localizing a lesion to a particular region can be helpful for the referring
clinician, surgeons generally need localization that is more precise. Using
combined PET/CT, provided the coregistration is accurate, the precise
localization of lesions obscured by artifacts is possible
(Fig. 2).

View larger version (74K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2. PET lesions obscured by artifact: Restaging PET/CT in patient
with history of squamous cell carcinoma of the right posterior oropharynx and
right neck who underwent right modified neck dissection and radiation therapy
and now presents with new onset of left-sided throat pain. Focal area of
intense FDG uptake noted on PET would be difficult or impossible to localize
without fusion images due to CT artifact obscuring anatomic detail. Fused
image localizes the PET abnormality to left retromolar trigone area
(arrows).
|
|
Identification of Normal-Sized Malignant Nodes
There are general size criteria for characterizing a lymph node as abnormal
depending on its location and, in general, normal-sized lymph nodes range in
size from less than 1 cm up to about 1.5 cm. In addition, necrosis generally
suggests a pathologic process. However, many malignant lymph nodes appear
normal in size and do not show abnormal enhancement or necrosis, particularly
in the early stages of disease. In these cases, PET is very useful for
detecting the presence of tumor within a node, as long it is larger than the
spatial resolution of the scanner (typically > 6 mm). PET/CT typically is
more useful in cases where there is more than one normalsized lymph node in
close proximity, but only one or two of them are hypermetabolic
(Fig. 3). In these cases, it is
possible to identify and convey to a surgeon which lymph nodes that appear
normal are actually involved with tumor. Before PET or PET/CT, these patients
often were followed with serial CT until the nodes grew large enough to be
confidently called malignant or until there was visible necrosis.

View larger version (90K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 3. Assessing the mediastinum: Select images from a staging
PET/CT examination in patient with recently diagnosed left lower lobe squamous
cell lung carcinoma. Axial CT images show normal-sized subcarinal and right
paratracheal lymph nodes with intense FDG uptake that are exquisitely
localized to otherwise normal-appearing lymph nodes on fused PET/CT images
(arrows), making the patient stage IIIB and a nonsurgical
candidate.
|
|
Improved Biopsy Localization Information
To increase the chances of making an accurate diagnosis with a positive
biopsy, it is important to direct the biopsy to the most metabolically active
portion of the mass, or if there are two nodules or masses in the same
vicinity, the more metabolically active lesion should be targeted for
sampling. With PET/CT, accurate biopsy sampling is possible by examining the
fused PET/CT images and directing the biopsy to the area of highest metabolic
activity (Fig. 4). However,
because contrast typically is not used for CT-guided biopsies, it often will
be necessary to print representative fused images for reference during the
biopsy procedure.

View larger version (80K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 4. Improved biopsy localization information: Select images from
PET/CT study patient with a history of colorectal cancer and rising
carcinoembryonic (CEA) levels. Images show a focal abnormality on PET images
that appears to correlate to "stable" presacral mass on CT.
Inspection of fused image shows only small portion of mass to be
hypermetabolic (arrows), which led to more focused CT-guided biopsy
proving recurrent adenocarcinoma.
|
|
Exclusion of Suspicious Lesions on Other Imaging
PET and PET/CT offer metabolic data not obtainable via anatomic imaging
techniques that can be used to evaluate further suspicious or equivocal
lesions found via other imaging techniques. By confirming or excluding the
presence of tumor in these patients, patient management often is affected.
Before PET/CT, patients might undergo additional surgical resection or at
least biopsy sampling to determine whether areas appearing suspicious on CT or
MRI were definitely involved with tumor. Clearly, PET/CT will have an
increasing role in differentiating posttreatment changes or anatomic variants
from residual or recurrent tumor, particularly before surgery.
Conclusion
Combined PET/CT has redefined the gold standard for oncologic imaging.
However, along with the many benefits of this new technique, come a set of
complex training, logistical, and legal concerns that will require careful
consideration and cooperation to determine the appropriate solutions. The
situation is certainly more complex than was envisioned at the introduction of
the technology. There also are questions as to what role PET/CT will have with
neurologic applications in which, for several reasons, PET alone may be the
preferred technique. Given the expansive interest in combined PET/CT, it is
clear that both referring and interpreting physicians must get the proper
training, and that standards are needed for future trainees. With the proper
cross-training, many of the legal concerns will be mitigated. Other
interpretation, reporting, and billing issues also will need considerable
attention to solve these complex questions in a way that benefits all parties
involved, but with patients being the ultimate beneficiaries.
References
- Slomka PJ. Software approach to merging molecular with anatomic
information. J Nucl Med2004; 45[suppl 1]:36S
-45S
- Slomka PJ, Dey D, Przetak C, Aladl UE, Baum RP. Automated
3-dimensional registration of stand-alone (18)F-FDG whole-body PET with CT.
J Nucl Med2003; 44:1156
-1167[Abstract/Free Full Text]
- Rodriguez-Carranza CE, Loew MH. Design and evaluation of an
automatic procedure for detection of large misregistration of medical images.
IEEE Trans Med Imaging2003; 22:1445
-1457[Medline]
- Levin DN, Pelizzari CA, Chen GT, Chen CT, Cooper MD. Retrospective
geometric correlation of MR, CT, and PET images.
Radiology1988; 169:817
-823[Abstract/Free Full Text]
- Pietrzyk U, Herholz K, Schuster A, von Stockhausen HM, Lucht H,
Heiss WD. Clinical applications of registration and fusion of multimodality
brain images from PET, SPECT, CT, and MRI. Eur J
Radiol 1996;21:174
-182[Medline]
- West J, Fitzpatrick JM, Wang MY, et al. Comparison and evaluation
of retrospective intermodality brain image registration techniques.
J Comput Assist Tomogr1997; 21:554
-566[Medline]
- Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear
medicine imaging in three-dimensional radiation treatment planning for lung
cancer: challenges and prospects. Lung Cancer1999; 23:105
-114[Medline]
- Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance
of PET/CT in evaluation of cancer: additional value for diagnostic imaging and
patient management. J Nucl Med2003; 44:1200
-1209[Abstract/Free Full Text]
- Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET
diagnostic accuracy: improvement with in-line PET-CT system: initial results.
Radiology2002; 225:575
-581[Abstract/Free Full Text]
- Osman MM, Cohade C, Nakamoto Y, Marshall LT, Leal JP, Wahl RL.
Clinically significant inaccurate localization of lesions with PET/CT:
frequency in 300 patients. J Nucl Med2003; 44:240
-243[Abstract/Free Full Text]
- Israel O, Mor M, Gaitini D, et al. Combined functional and
structural evaluation of cancer patients with a hybrid camera-based PET/CT
system using (18)F-FDG. J Nucl Med2002; 43:1129
-1136[Abstract/Free Full Text]
- Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for
lesion localisation in cancer patients: a comparative study. Eur J
Nucl Med Mol Imaging 2004;31
: 932-939[Medline]
- Yeretsian RA, Blodgett TM, Branstetter BFt, Roberts MM, Meltzer CC.
Teflon-induced granuloma: a false-positive finding with PET resolved with
combined PET and CT. Am J Neuroradiol2003; 24:1164
-1166[Abstract/Free Full Text]
- Bar-Shalom R, Gaitini D, Keidar Z, Israel O. Non-malignant FDG
uptake in infra-diaphragmatic adipose tissue: a new site of physiological
tracer biodistribution characterised by PET/CT. Eur J Nucl Med Mol
Imaging 2004;31:1105
-1113[Medline]
- Chander S, Meltzer CC, McCook BM. Physiologic uterine uptake of FDG
during menstruation demonstrated with serial combined positron emission
tomography and computed tomography. Clin Nucl Med2002; 27:22
-24[Medline]
- Kamel EM, Goerres GW, Burger C, von Schulthess GK, Steinert HC.
Recurrent laryngeal nerve palsy in patients with lung cancer: detection with
PET-CT image fusionreport of six cases.
Radiology2002; 224:153
-156[Abstract/Free Full Text]
- Keidar Z, Engel A, Nitecki S, Bar-Shalom R, Hoffman A, Israel O.
PET/CT using 2-deoxy-2-[18F]fluoro-D-glucose for the evaluation of suspected
infected vascular graft. Mol Imaging Biol2003; 5:23
-25[Medline]
- Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake
in the aortic wall at PET/CT: possible finding for active atherosclerosis.
Radiology 2003;229
: 831-837[Abstract/Free Full Text]
- Heller MT, Meltzer CC, Fukui MB, et al. Superphysiologic FDG uptake
in the non-paralyzed vocal cord. Resolution of a false-positive PET result
with combined PET-CT imaging. Clin Positron Imaging2000; 3:207
-211[Medline]
- Goerres GW, Von Schulthess GK, Hany TF. Positron emission
tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in
benign lesions, and in changes resulting from treatment.
AJR 2002;179:1337
-1343[Free Full Text]
- Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular
area fat ("USA-Fat"): description on 18F-FDG PET/CT. J
Nucl Med 2003;44:170
-176[Abstract/Free Full Text]
- Weiss N, Solomon SB. Talc pleurodesis mimics pleural metastases:
differentiation with positron emission tomography/computed tomography.
Clin Nucl Med2003; 28:811
-814[Medline]
- Scarfone C, Lavely WC, Cmelak AJ, et al. Prospective feasibility
trial of radiotherapy target definition for head and neck cancer using
3-dimensional PET and CT imaging. J Nucl Med2004; 45:543
-552[Abstract/Free Full Text]
- Bradley JD, Perez CA, Dehdashti F, Siegel BA. Implementing biologic
target volumes in radiation treatment planning for non-small cell lung cancer.
J Nucl Med2004; 45[suppl 1]:96S
-101S
- Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on
radiation therapy volume delineation in non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys2004; 59:78
-86[Medline]
- Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment
planning with an integrated positron emission and computer tomography
(PET/CT): a feasibility study. Int J Radiat Oncol Biol
Phys 2003;57:853
-863[Medline]
- Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult
recurrent ovarian cancer: patient selection for secondary cytoreductive
surgery using combined PET/CT. Gynecol Oncol2003; 90:519
-528[Medline]
- Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer:
dual-modality PET/CT in preoperative staging.
Radiology2003; 229:526
-533[Abstract/Free Full Text]
- Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and
Hodgkin disease: coregistered FDG PET and CT at staging and restagingdo
we need contrast-enhanced CT? Radiology2004; 232:823
-829[Abstract/Free Full Text]
- Ollenberger GP. Staging of lung cancer with integrated PET-CT.
N Engl J Med2004; 350:86
-87;author reply 86-87[Free Full Text]
- Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell
lung cancer with integrated positron-emission tomography and computed
tomography. N Engl J Med2003; 348:2500
-2507[Abstract/Free Full Text]
- Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG
PET and PET/CT in patients with colorectal carcinoma. J Nucl
Med 2003;44:1797
-1803[Abstract/Free Full Text]
- Martinelli M, Townsend D, Meltzer C, Villemagne VV. 7. Survey of
results of whole body imaging using the PET/CT at the University of Pittsburgh
Medical Center PET facility. Clin Positron Imaging2000; 3:161[Medline]
- Kluetz P, Villemagne VV, Meltzer C, Chander S, Martinelli M,
Townsend D. 20. The case for PET/CT. Experience at the University of
Pittsburgh. Clin Positron Imaging2000; 3:174[Medline]
- Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in
patients with persistent ovarian cancer: correlation with histologic findings.
Radiology2004; 233:433[Abstract/Free Full Text]
- Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in
recurrent ovarian cancer: initial observations.
RadioGraphics2004; 24:209
-223[Abstract/Free Full Text]
- Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET-CT
detection of abdominal recurrence of ovarian cancer: radiologic-surgical
correlation. Abdom Imaging2004; 29:398
-403[Medline]
- Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL. Incremental
value of CT in PET/CT of patients with colorectal carcinoma. Abdom
Imaging 2004;29:663
-668[Medline]
- Branstetter BF, Blodgett TM, Zimmer LA, Snyderman CH, Johnson JT,
Raman S, Meltzer CC. Depiction of head and neck malignancy: is PET/CT more
accurate than PET or CT alone? Radiology (in
press)
- Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and
dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in
patients with gastrointestinal stromal tumors. J Nucl
Med 2004;45:357
-365[Abstract/Free Full Text]
- Zimmer LA, McCook B, Meltzer C, et al. Combined positron emission
tomography/computed tomography imaging of recurrent thyroid cancer.
Otolaryngol Head Neck Surgery2003; 128:178
-184[Medline]
- Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC.
Positron emission tomography/computed tomography imaging for the detection of
recurrent ovarian and fallopian tube carcinoma: a retrospective review.
Gynecol Oncol2002; 85:53
-58[Medline]

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Z. Wong, E. K. Paulson, R. C. Nelson, E. F. Patz Jr., and R. E. Coleman
Practical Approach to Diagnostic CT Combined with PET
Am. J. Roentgenol.,
March 1, 2007;
188(3):
622 - 629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Bruzzi, M. T. Truong, E. M. Marom, O. Mawlawi, D. A. Podoloff, H. A. Macapinlac, and R. F. Munden
Incidental Findings on Integrated PET/CT That Do Not Accumulate 18F-FDG
Am. J. Roentgenol.,
October 1, 2006;
187(4):
1116 - 1123.
[Abstract]
[Full Text]
[PDF]
|
 |
|